Clinical Trials on Primary Thrombocytosis

Total 59779 results

Taipei Medical University WanFang Hospital

Completed

Childhood Reactive Thrombocytosis (RT)

Reactive Thromobocytosis in Children

Taiwan
Nanfang Hospital, Southern Medical University

Recruiting

The Role of Circ0014614 in the Formation and Development of ET

Primary Thrombocytosis

China
Assiut University

Not yet recruiting

Aetiology And Outcome Of Children With Thrombocytosis Admitted to Assiut University Children Hospital

Thrombocytosis in Children
M.D. Anderson Cancer Center
Active Biotech AB

Not yet recruiting

Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-Essential Thrombocytosis Myelofibrosis

United States
National Institutes of Health Clinical Center (CC)

Completed

Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders

Polycythemia Vera | Chronic Myeloproliferative Disorders | Essential Thrombocytosis | Idiopathic Myelofibrosis | Neutrophils

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Novartis Pharmaceuticals

Completed

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase

United States
Hamad Medical Corporation

Unknown

18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia (PMF/ET-FLT)

Essential Thrombocythemia | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic Stage

Qatar
University Hospital, Angers

Recruiting

Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. (BioScoreSMP)

Essential Thrombocythemia | Myeloproliferative Disorder | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic Stage

France
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts

Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified | Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified

United States
Novartis Pharmaceuticals

Completed

INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. (JUMP)

Myelofibrosis

Belgium, Colombia, Canada, Italy, Spain, Austria, Germany, Czechia, Thailand, Hungary, Greece, Argentina, Brazil, Israel, Russian Federation, Mexico, Portugal, South Africa, Tunisia, Slovakia, Saudi Arabia, Poland, Algeria, Ireland, Mor...
Imago BioSciences, Inc., a subsidiary of Merck...

Active, not recruiting

Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

Primary Myelofibrosis | Thrombocythemia, Essential

United States, Australia, Hong Kong, Germany, Italy, New Zealand, United Kingdom
Cephalon

Completed

Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

Polycythemia Vera | Essential Thrombocytosis

United States
M.D. Anderson Cancer Center
Celgene

Completed

Pomalidomide for Myelofibrosis Patients

Polycythemia Vera | Thrombocythemia

United States
University Hospital, Angers
Ligue contre le cancer, France

Recruiting

Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) (CALRSUIVI)

Essential Thrombocythemia | Myeloproliferative Neoplasm | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic Stage

France
Incyte Corporation

Completed

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Polycythemia Vera | Myelofibrosis | Thrombocythemia

Spain, United States, Germany, Austria, Belgium, Italy, Poland
Novartis Pharmaceuticals

Completed

A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis

Primary Myelofibrosis (MF)

Japan
Novartis Pharmaceuticals

Completed

Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) (MACS2030)

Primary Myelofibrosis (PMF) | Post Polycythaemia Myelofibrosis (PPV MF) | Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

United Kingdom
University of Cambridge
Cambridge University Hospitals NHS Foundation Trust; Institute of Cancer Research...

Completed

Primary Thrombocythaemia 1 Trial (PT-1)

Myeloproliferative Disorder | Thrombocythemia

United Kingdom
Hamad Medical Corporation

Terminated

18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms

Polycythemia Vera | Essential Thrombocythemia | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic Stage

Qatar
Incyte Corporation

Completed

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

MPN (Myeloproliferative Neoplasms)

United States, Puerto Rico
Constellation Pharmaceuticals
The Leukemia and Lymphoma Society

Active, not recruiting

A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

Neoplasms | Neoplasms by Histologic Type | Leukemia | Preleukemia | Primary Myelofibrosis | Myeloproliferative Disorders | Myelofibrosis | Precancerous Conditions | Myelodysplastic/Myeloproliferative Neoplasm | Myelodysplastic Syndrome (MDS) | Leukemia, Myelocytic, Acute | Bone Marrow Disease | Hematological Disease and other conditions

Canada, United States, United Kingdom, Germany, Italy, Belgium, France, Netherlands, Poland
Eli Lilly and Company

Completed

A Study in Myeloproliferative Disorders

Primary Myelofibrosis | Myeloproliferative Disorders | Polycythemia Vera | Thrombocythemia, Essential

United States
University of Utah
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Molecular Biology of Polycythemia and Thrombocytosis

Polycythemia | Thrombocytosis

United States
Terumo BCT

Completed

Retrospective Data Collection of Routine Use With Spectra Optia® for Platelet Depletions (PLTD)

Thrombocytosis | Thrombocythemia | Myeloproliferative Disease

Denmark, Hungary
Exelixis

Terminated

A Safety Study of XL019 in Adults With Myelofibrosis

Myeloproliferative Disorders | Polycythemia Vera | Thrombocythemia, Essential | Myelofibrosis

United States
AstraZeneca
University of Texas; Gustave Roussy, Cancer Campus, Grand Paris; New York City...

Completed

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

Primary Myelofibrosis (PMF) | Post-Polycythaemia Vera | Essential Thrombocythaemia Myelofibrosis

United States, France
Celgene

Active, not recruiting

A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Primary Myelofibrosis

Japan
Federico II University

Completed

Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative Neoplasm | Prefibrotic/Early Primary Myelofibrosis

Italy
Queen's University, Belfast
Mayo Clinic; University Hospital Southampton NHS Foundation Trust; University... and other collaborators

Completed

Myeloproliferative Neoplasms: an In-depth Case-control Study (MOSAICC)

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia

United Kingdom
The University of Hong Kong
Novartis

Recruiting

Asian Myeloproliferative Neoplasm (MPN) Registry

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative Neoplasm | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic Stage

Hong Kong
Imago BioSciences, Inc., a subsidiary of Merck...

Completed

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

Myelofibrosis | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (PPV-MF) | Post-essential Thrombocythemia Myelofibrosis (PET-MF)

Germany, United States, Australia, Italy, United Kingdom
Novartis Pharmaceuticals

Completed

Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

Primary Myelofibrosis (MF) | Post-Polycythemia Vera (PV) MF | Post-Essential Thrombocythemia (ET) MF

Taiwan, Japan, Korea, Republic of, China
University Hospital, Brest

Recruiting

Myeloproliferative Neoplastic Diseases Observatory From Brest (OBENE)

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia

France
Incyte Corporation

Completed

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Polycythemia Vera | Thrombocytosis | Myelofibrosis

United States
Kartos Therapeutics, Inc.

Recruiting

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Myelofibrosis

United States, France, Australia, Spain, Germany, Bulgaria, Israel, Italy, Poland
Roswell Park Cancer Institute
Cephalon, Inc.

Terminated

Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia

United States
Gilead Sciences

Terminated

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease (Madison)

Myelofibrosis

United States
Memorial Sloan Kettering Cancer Center
Novartis

Terminated

HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET

Myeloproliferative Neoplasms

United States
Ronald Hoffman
National Cancer Institute (NCI); Myeloproliferative Disorders-Research Consortium

Unknown

CEP-701 (Lestaurtinib) in Myelofibrosis

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis

United States
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Icahn School of Medicine at Mount Sinai
National Cancer Institute (NCI); Myeloproliferative Disorders-Research Consortium

Completed

Familial Myeloproliferative Disorders

Polycythemia Vera | Essential Thrombocythemia | Idiopathic Myelofibrosis

United States, Italy
Fox Chase Cancer Center

Recruiting

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Primary Myelofibrosis | Polycythemia Vera | Chronic Myelomonocytic Leukemia | Essential Thrombocytosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States
Syntara
Parexel

Recruiting

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Myelofibrosis

Taiwan, Australia, Korea, Republic of, United States
Gilead Sciences

Completed

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

Myelofibrosis

United States
University of Utah
National Cancer Institute (NCI); Myeloproliferative Disorders-Research Consortium

Completed

Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis

United States
S*BIO

Completed

A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis

Myeloproliferative Disorders | Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis

United States, Australia
Thomas Stauffer Larsen

Completed

A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms (DALIAH)

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia

Denmark
University Hospital, Angers
Poitiers University Hospital; University Hospital, Brest; Rennes University Hospital and other collaborators

Not yet recruiting

Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis. (BioPredictor)

Myeloproliferative Neoplasm
Galena Biopharma, Inc.

Completed

A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders

Thrombocytosis | Myeloproliferative Neoplasms

United States
Kartos Therapeutics, Inc.

Recruiting

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)

Primary Myelofibrosis (PMF) | Post-Polycythemia Vera MF (Post-PV-MF) | Post-Essential Thrombocythemia MF (Post-ET-MF)

United States, Korea, Republic of, Germany, Australia, Hungary, France, Spain, Italy, Taiwan, Thailand, Brazil, Poland, Turkey, Israel, Portugal, Romania, Argentina, Bulgaria, Canada, Croatia, Czechia, Lithuania, Mexico, Philippines, United... and more

Clinical Trials on Primary Thrombocytosis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations